Microbot Medical Stock-Based Compensation Growth & History (MBOT)
Microbot Medical's stock-based compensation was $1.1M for fiscal 2025.
View full Microbot Medical company overviewMicrobot Medical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$292,000 | −21.65% |
| 2024 | 2024-12-31 | $1.3M | −$45,000 | −3.23% |
| 2023 | 2023-12-31 | $1.4M | −$358,000 | −20.43% |
| 2022 | 2022-12-31 | $1.8M | $366,000 | +26.41% |
| 2021 | 2021-12-31 | $1.4M | −$551,000 | −28.45% |
| 2020 | 2020-12-31 | $1.9M | $838,000 | +76.25% |
| 2019 | 2019-12-31 | $1.1M | −$300,000 | −21.44% |
| 2018 | 2018-12-31 | $1.4M | $920,000 | +192.07% |
| 2017 | 2017-12-31 | $479,000 | −$197,000 | −29.14% |
| 2016 | 2016-12-31 | $676,000 | −$3.6M | −84.07% |
| 2015 | 2015-12-31 | $4.2M | $2.2M | +108.58% |
| 2014 | 2014-12-31 | $2.0M | −$573,772 | −21.99% |
| 2013 | 2013-12-31 | $2.6M | −$269,464 | −9.36% |
| 2012 | 2012-12-31 | $2.9M | −$382,803 | −11.74% |
| 2011 | 2011-12-31 | $3.3M | −$668,697 | −17.02% |
| 2010 | 2010-12-31 | $3.9M | −$273,636 | −6.51% |
| 2009 | 2009-12-31 | $4.2M | — | — |
Microbot Medical quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $433,000 | $196,000 | +82.70% |
| Q1 2026 | 2026-03-31 | $222,000 | −$34,000 | −13.28% |
| Q4 2025 | 2025-12-31 | $236,000 | −$46,000 | −16.31% |
| Q3 2025 | 2025-09-30 | $328,000 | $45,000 | +15.90% |
| Q2 2025 | 2025-06-30 | $237,000 | −$94,000 | −28.40% |
| Q1 2025 | 2025-03-31 | $256,000 | −$197,000 | −43.49% |
| Q4 2024 | 2024-12-31 | $282,000 | −$15,000 | −5.05% |
| Q3 2024 | 2024-09-30 | $283,000 | −$53,000 | −15.77% |
| Q2 2024 | 2024-06-30 | $331,000 | −$18,000 | −5.16% |
| Q1 2024 | 2024-03-31 | $453,000 | $41,000 | +9.95% |
| Q4 2023 | 2023-12-31 | $297,000 | −$133,000 | −30.93% |
| Q3 2023 | 2023-09-30 | $336,000 | −$125,000 | −27.11% |
| Q2 2023 | 2023-06-30 | $349,000 | −$83,000 | −19.21% |
| Q1 2023 | 2023-03-31 | $412,000 | −$17,000 | −3.96% |
| Q4 2022 | 2022-12-31 | $430,000 | $60,000 | +16.22% |
| Q3 2022 | 2022-09-30 | $461,000 | $154,000 | +50.16% |
| Q2 2022 | 2022-06-30 | $432,000 | $133,000 | +44.48% |
| Q1 2022 | 2022-03-31 | $429,000 | $19,000 | +4.63% |
| Q4 2021 | 2021-12-31 | $370,000 | −$99,000 | −21.11% |
| Q3 2021 | 2021-09-30 | $307,000 | −$252,000 | −45.08% |
| Q2 2021 | 2021-06-30 | $299,000 | −$267,000 | −47.17% |
| Q1 2021 | 2021-03-31 | $410,000 | $67,000 | +19.53% |
| Q4 2020 | 2020-12-31 | $469,000 | $276,000 | +143.01% |
| Q3 2020 | 2020-09-30 | $559,000 | $263,000 | +88.85% |
| Q2 2020 | 2020-06-30 | $566,000 | $271,000 | +91.86% |
| Q1 2020 | 2020-03-31 | $343,000 | $28,000 | +8.89% |
| Q4 2019 | 2019-12-31 | $193,000 | −$141,000 | −42.22% |
| Q3 2019 | 2019-09-30 | $296,000 | $53,000 | +21.81% |
| Q2 2019 | 2019-06-30 | $295,000 | −$111,000 | −27.34% |
| Q1 2019 | 2019-03-31 | $315,000 | −$101,000 | −24.28% |
| Q4 2018 | 2018-12-31 | $334,000 | $31,000 | +10.23% |
| Q3 2018 | 2018-09-30 | $243,000 | $221,000 | +1004.55% |
| Q2 2018 | 2018-06-30 | $406,000 | $252,000 | +163.64% |
| Q1 2018 | 2018-03-31 | $416,000 | $416,000 | — |
| Q4 2017 | 2017-12-31 | $303,000 | — | — |
| Q3 2017 | 2017-09-30 | $22,000 | — | — |
| Q2 2017 | 2017-06-30 | $154,000 | $154,000 | — |
| Q1 2017 | 2017-03-31 | $0 | −$1.9M | — |
| Q2 2016 | 2016-06-30 | $0 | −$1.4M | — |
| Q1 2016 | 2016-03-31 | $1.9M | $543,532 | +41.53% |
| Q4 2015 | 2015-12-31 | $157,698 | −$333,623 | −67.90% |
| Q3 2015 | 2015-09-30 | $1.4M | $917,431 | +180.31% |
| Q2 2015 | 2015-06-30 | $1.4M | $837,914 | +163.13% |
| Q1 2015 | 2015-03-31 | $1.3M | $787,788 | +151.18% |
| Q4 2014 | 2014-12-31 | $491,321 | −$84,121 | −14.62% |
| Q3 2014 | 2014-09-30 | $508,811 | −$88,194 | −14.77% |
| Q2 2014 | 2014-06-30 | $513,660 | −$235,981 | −31.48% |
| Q1 2014 | 2014-03-31 | $521,106 | −$165,476 | −24.10% |
| Q4 2013 | 2013-12-31 | $575,442 | −$75,547 | −11.60% |
| Q3 2013 | 2013-09-30 | $597,005 | −$170,150 | −22.18% |
| Q2 2013 | 2013-06-30 | $749,641 | $26,196 | +3.62% |
| Q1 2013 | 2013-03-31 | $686,582 | −$49,963 | −6.78% |
| Q4 2012 | 2012-12-31 | $650,989 | $26,497 | +4.24% |
| Q3 2012 | 2012-09-30 | $767,155 | $79,437 | +11.55% |
| Q2 2012 | 2012-06-30 | $723,445 | −$290,818 | −28.67% |
| Q1 2012 | 2012-03-31 | $736,545 | −$197,919 | −21.18% |
| Q4 2011 | 2011-12-31 | $624,492 | — | — |
| Q3 2011 | 2011-09-30 | $687,718 | −$177,652 | −20.53% |
| Q2 2011 | 2011-06-30 | $1.0M | — | — |
| Q1 2011 | 2011-03-31 | $934,464 | — | — |
| Q3 2010 | 2010-09-30 | $865,370 | — | — |
Microbot Medical stock-based compensation trends
Over the last five fiscal years, Microbot Medical's stock-based compensation decreased from $1.9M to $1.1M, a change of −$880,000. The latest reported quarter, Q2 2026, shows $433,000.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Microbot Medical source filings ↗